Tenderwize
Zurück zur Suche

Open house Arzneimittelrabattverträge Repaglinid, ATC A10BX02

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 03, 2028 · 493 days left·Open·Supplies·Framework
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Repaglinid, ATC A10BX02

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

30 / 100

Risikofaktoren

No estimated value or guaranteed volume. Revenues depend on actual prescriptions and market share.

Contracts are automatically terminated if a competitive discount contract for Repaglinide is concluded by AOK Bayern or...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Provision of the pharmaceutical product Repaglinide (ATC A10BX02) under non-exclusive discount agreements with AOK Bayern.
  • Contracts are identical and non-negotiable for all participating pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is an open-house model (not a standard procurement) by AOK Bayern for non-exclusive discount agreements on the active substance Repaglinide (ATC A10BX02). All interested pharmaceutical companies that meet the eligibility criteria can enter into identical, non-negotiable contracts. The contract runs from 01.03.2026 to 29.02.2028, with possible termination on one month's notice. No estimated value is provided. The procedure is open to all, with no competitive award criteria. Documentation is available online via DTVP portal.

Risiken

No estimated value or guaranteed volume. Revenues depend on actual prescriptions and market share.

Contracts are automatically terminated if a competitive discount contract for Repaglinide is concluded by AOK Bayern or...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible.
  • Eligibility is demonstrated by a signed declaration of reliability.

Administrative

  • Contract must be submitted in two original copies (if paper) or with qualified electronic signature (if electronic).

Anforderungen können unvollständig sein.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house Arzneimittelrabattverträge Repaglinid, ATC A10BX02

Non-exclusive discount agreements for Repaglinide (ATC A10BX02). Contract duration 01.03.2026 - 29.02.2028. Contracts can be concluded any time until 03.01.2028. Submission deadlines: 3rd of each month for start next month, or 10th for paper originals.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Feb 2026 - Feb 2028

Kategorie

Pharmaceutical products

Frist

Deadline Jan 03, 2028

Vergabedetails

Veröffentlichungsdatum
13 Jan 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
26721-2026

Dokumente (2)

Ähnliche Ausschreibungen